These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1925544)

  • 41. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
    Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S
    Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transmission blocking antibody of the Plasmodium falciparum zygote/ookinete surface protein Pfs25 also influences sporozoite development.
    Lensen AH; Van Gemert GJ; Bolmer MG; Meis JF; Kaslow D; Meuwissen JH; Ponnudurai T
    Parasite Immunol; 1992 Sep; 14(5):471-9. PubMed ID: 1437237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
    Gozar MM; Muratova O; Keister DB; Kensil CR; Price VL; Kaslow DC
    Exp Parasitol; 2001 Feb; 97(2):61-9. PubMed ID: 11281702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast.
    Moelans II; Cohen J; Marchand M; Molitor C; de Wilde P; van Pelt JF; Hollingdale MR; Roeffen WF; Eling WM; Atkinson CT
    Mol Biochem Parasitol; 1995 Jun; 72(1-2):179-92. PubMed ID: 8538688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
    Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
    Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
    Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice.
    Gozar MM; Price VL; Kaslow DC
    Infect Immun; 1998 Jan; 66(1):59-64. PubMed ID: 9423839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.
    Singh SK; Roeffen W; Andersen G; Bousema T; Christiansen M; Sauerwein R; Theisen M
    Vaccine; 2015 Apr; 33(16):1981-6. PubMed ID: 25728318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
    Kubler-Kielb J; Majadly F; Wu Y; Narum DL; Guo C; Miller LH; Shiloach J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):293-8. PubMed ID: 17190797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of a continuous and cross-reacting epitope for Plasmodium falciparum transmission-blocking immunity.
    Wizel B; Kumar N
    Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9533-7. PubMed ID: 1719534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An experimental vaccine cocktail for Plasmodium falciparum malaria.
    Bathurst IC; Gibson HL; Kansopon J; Hahm BK; Green KM; Chang SP; Hui GS; Siddiqui WA; Inselburg J; Millet P
    Vaccine; 1993; 11(4):449-56. PubMed ID: 8470430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel monoclonal antibody against truncated C terminal region of Histidine Rich Protein2 (PfHRP2) and its utility for the specific diagnosis of malaria caused by Plasmodium falciparum.
    Verma R; Jayaprakash NS; Vijayalakshmi MA; Venkataraman K
    Exp Parasitol; 2015 Mar; 150():56-66. PubMed ID: 25592728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.
    Coelho CH; Nadakal ST; Gonzales Hurtado P; Morrison R; Galson JD; Neal J; Wu Y; King CR; Price V; Miura K; Wong-Madden S; Alamou Doritchamou JY; Narum DL; MacDonald NJ; Snow-Smith M; Vignali M; Taylor JJ; Lefranc MP; Trück J; Long CA; Healy SA; Sagara I; Fried M; Duffy PE
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33048842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose.
    Kaslow DC; Shiloach J
    Biotechnology (N Y); 1994 May; 12(5):494-9. PubMed ID: 7764708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain.
    Moll K; Pettersson F; Vogt AM; Jonsson C; Rasti N; Ahuja S; Spångberg M; Mercereau-Puijalon O; Arnot DE; Wahlgren M; Chen Q
    Infect Immun; 2007 Jan; 75(1):211-9. PubMed ID: 17074852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.